Tudor Investment Corporation »

Enliven Therapeutics shares owned by Tudor Investment Corporation

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Tudor Investment Corporation from 13F filings

Historical chart of Tudor Investment Corporation investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Tudor Investment Corporation consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Tudor Investment Corporation

Quarter filed Position value Share count Share price at filing
2025-09-30 $334k 16k 20.47
2025-03-31 $263k 13k 19.68
2024-06-30 $566k 24k 23.37

More positions owned by Tudor Investment Corporation

Ishares Russell 2000 Etf - US ETP ETF Option Call Option (IWM)
Invesco Qqq Trust Series 1 - US ETP ETF Option Call Option (QQQ)
Spdr S&P 500 Etf Trust - US ETP ETF Option Call Option (SPY)
Energy Select Sector Spdr Fund - US ETP ETF Option Call Option (XLE)
Ishares China Large-Cap Etf - US ETP ETF Option Call Option (FXI)
Nvidia Corp - US Equity (NVDA)
Ishares Msci Emerging Markets Etf - US ETP ETF Option Call Option (EEM)
Unitedhealth Group Inc - US Equity (UNH)
Utilities Select Sector Spdr Fund - US ETP ETF Option Call Option (XLU)
Financial Select Sector Spdr Fund - US ETP ETF Option Call Option (XLF)
Palantir Technologies Inc - US Equity (PLTR)
Oracle Corp - US Equity Option Call Option (ORCL)
Micron Technology Inc - US Equity (MU)
Goldman Sachs Group Inc/The - US Equity Option Call Option (GS)
Apple Inc - US Equity (AAPL)

View all positions for Tudor Investment Corporation

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
Commodore Capital
Fairmount Funds Management
BlackRock
VR Adviser
Polar Capital Holdings
Vanguard Group
Henderson Group
Novo A/S
Pictet Asset Management Holding SA
Blackstone Group
Capital Research Global Investors
Citadel Advisors
Vestal Point Capital

View all funds holding Enliven Therapeutics